GMDA News and Press, Gamida Cell Ltd. From 01/02/20

– Topline data expected in first half of 2020 – Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, announced that in December the company completed patient enrollment in its Phase 3 ...

Gainers: EQ   +17.3% . SFIX   +12.2% . GNW   +10.1% . MDB   +5.6% . GMDA   +4.0% . More news on: Equillium, Inc., Stitch Fix, Inc., Genworth Financial, Inc., Stocks on the move, Read more ...

— GDA-201 demonstrated early evidence of clinical activity in patients with non-Hodgkin lymphoma, with multiple complete responses observed — — Research on mechanism of action for the NAM technology platform provides further scientific rationale for stem cell engra...

Treating patients through stem cell research and regenerative medicines has emerged in popularity in the life sciences sector, although controversy has circulated this relatively new and upcoming therapeutic area for years. As described by the US National Institutes of Health , stem cells...

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph.D., the company’s chief executive officer, will participate in a “fireside chat” at the 31 st ...

Gamida Cell Ltd. (GMDA) Q3 2019 Earnings Conference Call November 13, 2019, 16:30 PM ET Company Participants Jaren Madden - VP of IR Julian Adams - CEO Ronit Simantov - CMO Tracey Lodie - Chief Scientific Officer Shai Lankry - Chief Financial Officer Conference Call Partic...

Gamida Cell (NASDAQ: GMDA ): Q3 GAAP EPS of -$0.30 beats by $0.09 . Press Release More news on: Gamida Cell Ltd., Earnings news and commentary, Healthcare stocks news, ,

– Completion of patient enrollment in Phase 3 clinical study of omidubicel expected by year-end; Topline data anticipated in first half of 2020 – – Additional results from Phase 1 study of GDA-201 and new data on NAM technology platform to be presented at 61 st An...

– Presentations to include updated results from Phase 1 study of GDA-201 and new data on mechanism of action for NAM cell expansion platform – Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that results from a Phase 1 ...

Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that the company will host a conference call and live audio webcast on Wednesday, November 13, 2019, at 4:30 p.m. ET to review its third quarter 2019 financial results and provide an update on...